创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

刘翠翠, 殷嘉妮, 蒋斯明, 邵阳. 胆管癌中成纤维细胞生长因子受体基因变异特点、靶向治疗及其伴随诊断的研究进展[J]. 药学进展, 2021, 45(1): 27-36.
引用本文: 刘翠翠, 殷嘉妮, 蒋斯明, 邵阳. 胆管癌中成纤维细胞生长因子受体基因变异特点、靶向治疗及其伴随诊断的研究进展[J]. 药学进展, 2021, 45(1): 27-36.
LIU Cuicui, YIN Jiani, JIANG Siming, SHAO Yang. Advances in Research on Fibroblast Growth Factor Receptors Alterations, Its Targeted Therapies and Companion Diagnosis[J]. Progress in Pharmaceutical Sciences, 2021, 45(1): 27-36.
Citation: LIU Cuicui, YIN Jiani, JIANG Siming, SHAO Yang. Advances in Research on Fibroblast Growth Factor Receptors Alterations, Its Targeted Therapies and Companion Diagnosis[J]. Progress in Pharmaceutical Sciences, 2021, 45(1): 27-36.

胆管癌中成纤维细胞生长因子受体基因变异特点、靶向治疗及其伴随诊断的研究进展

Advances in Research on Fibroblast Growth Factor Receptors Alterations, Its Targeted Therapies and Companion Diagnosis

  • 摘要: 胆管癌是一种罕见、异质性高且预后不良的恶性肿瘤,近年来肝内胆管癌的发病率呈上升趋势,由于其高度的异质性,胆管癌的治疗方法有限。近年来基因组学的研究发现接近一半的胆管癌患者携带潜在治疗靶点,其中成纤维细胞生长因子受体(FGFR)通路的激活,尤其是FGFR2基因的融合,是较常见的肝内胆管癌的发病机制。多种FGFR抑制剂的临床试验结果为携带FGFR2基因融合晚期胆管癌患者带来新的希望。通过对胆管癌中FGFR基因变异图谱及检测方法和伴随诊断进行综述,旨在探讨FGFR2融合在胆管癌中的驱动作用以及靶向治疗潜力。

     

    Abstract: Cholangiocarcinoma is a group of rare and heterogeneous malignancies characterized by poor clinical outcomes. In spite of the increasing incidence of intrahepatic cholangiocarcinoma (ICC), few treatment options exist for patients with advanced disease due to its aggressiveness and highly complex nature. Driven by the advances in large-scale genetic sequencing technologies, potentially targetable genetic alterations have been identified in nearly half of the cholangiocarcinoma patients. Activation of the fibroblast growth factor receptor (FGFR) pathway, particularly those caused by fibroblast growth factor receptor 2 (FGFR2) rearrangements, is a common mechanism underlying ICC pathogenesis. Clinical trials of FGFR inhibitors have demonstrated promising results in advanced stage cholangiocarcinoma harboring FGFR2 rearrangements. This paper discusses the mutational landscape, detection methods and companion diagnosis of FGFR family genes, aiming to explore the oncogenic role and potential therapeutic value of FGFR in cholangiocarcinoma.

     

/

返回文章
返回